ADRB3 and autosomal dominant polycystic kidney disease: Finally, although SR59230A shows poor selectivity for the human β3‐AR, this study constitutes the first proof of concept that β3‐AR can be successfully targeted to improve the cystic phenotype in ADPKD and supports further research into β3‐AR antagonists with a better translational profile.